In order to evaluate the potential role of immune checkpoint pathways in the reduction of ADCC over time, the effects of IFNγ treatment on PD-L1 and PD-L2 expression as well as Stat1 activation in neuroblastoma cells was evaluated. The gene discussed is PDCD1LG2; the disease is neuroblastoma.